Spinal Health News
-
Synaptive’s Modus X Takes Center Stage in the latest issue of the Journal of Neurosurgery’s Neurosurgical Focus on exoscopes in neurosurgery
January’s Journal of Neurosurgery (JNS) published a series of 17 videos that examine the application of exoscopic visualization in cerebrovascular, neuro-oncologic, pediatric, peripheral nerve, and spinal neurosurgery. The video series highlights the exoscope as a versatile alternative to traditional optical microcopy. Seven of the videos highlight the use of Synaptive’s robotic ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Advances in Newborn SMA Screening research by SNP Biotechnology
BSD Robotics is proud to share a recent study conducted by SNP Biotechnology R&D Ltd “A new line method; A direct test in spinal muscular atrophy screening for DBS” now published in the journal of Molecular Genetics and Genomic Medicine. Given spinal muscular atrophy (SMA) is one of the most prevalent genetic disorders affecting young children and a major cause of death in ...
By BSD Robotics
-
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
-
Caira Surgical to Participate in Upcoming Investor Conferences
Caira Surgical, the pioneer in radar surgical tracking for navigated and robotic joint replacement surgery, announced today that Jon Greenwald, Chief Executive Officer, and Irina Benimovich, Chief Financial Officer, will conduct investor meetings and host presentations at the upcoming CG 2023 Musculoskeletal Conference and LSI USA '23 partnering event. March 7 – CG 2023 Musculoskeletal ...
-
Meagan Medical Inc. Announces Issuance of a Key U.S. Patent for a Disruptive Chronic Pain Treatment using Spinal Cord Stimulation
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
-
FARCO-PHARMA supports “Protect the vulnerable“
Europe-wide aid project for the protection of people with paraplegia Cologne, 28/05/2020 – COVID-19 can be particularly dangerous for people with severe spinal cord injuries. That is why FARCO-PHARMA supports the European Spinal Cord Injury Federation (ESCIF) and the Association of Paraplegics in Germany e.V. (FGQ) with the supply of free protective masks for the caregivers of this ...
-
DIH-HERO project “EngageABLE”
We are pleased to announce that “EngageABLE”, a project of ABLE Human Motion in collaboration with the dutch hospital Sint Maartenskliniek, has been awarded for funding by DIH-HERO. The goal of this project is to enhance the capabilities of the ABLE Exoskeleton to promote users’ motivation and faster learning. DIH-HERO is an independent platform that connects Digital Innovation ...
-
Clinical investigations
We performed 2 clinical trials in leading neurorehabilitation hospitals in Germany and Spain proving safety, feasibility and usability of the exoskeleton in a clinical setting, and showing significant improvements in clinical outcomes and benefits in rehabilitation. A Multicentric Clinical investigation in Institut Guttmann (Spain) and Heidelberg University Hospital (Germany), leading European ...
-
Clinical benefits of exoskeletons
Helena López; why did you decide to become a physiotherapist? Because I like dealing with people, I like helping, I like healthcare… All these reasons were leading me towards medicine, but, in that case, I would spend little time with the patient. I preferred the contact, to be more involved in their evolution. And what made me decide, specifically for the field of neurology, was ...
-
Design freeze of ABLE Exoskeleton
After creating 7 iterative versions of the exoskeleton prototype that have been tested in individuals with spinal cord injury to validate product-market fit and receive early feedback in order to adapt, change and redesign the device, we have frozen the design of the ABLE Exoskeleton. The final design will be revealed at RehabWeek, the leading conference in rehabilitation technology, in Rotterdam ...
-
What do clinical experts say about the ABLE Exoskeleton?
We interviewed Prof. Dr. Ing. Rüdiger Rupp, a key opinion leader in the field of rehabilitation technology with more than 25 years of clinical experience, to talk about rehabilitation, exoskeleton technology, clinical trials and many more. Prof. Dr. Ing. Rüdiger Rupp is the Head of Experimental Neurorehabilitation at the Heidelberg University Hospital in Germany. Throughout his ...
-
The future of rehabilitation
Congratulations to the ONWARD team for the incredible progress they are making in the field of neuroengineering! In recent days, numerous media have reported the news of a great advance for science, and especially for all those people with spinal cord injury and their medical and caregiver teams. The ONWARD team has developed an epidural electrical stimulation system using electrodes placed ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with ...
-
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
-
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m. ET. Zuranolone is being evaluated as a potential rapid-acting, once-daily, oral two-week treatment for major ...
-
Differences Between Spinal Blocks & Epidurals
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. The reason for this difference is that the former is an anesthetic, while the latter is an analgesic—no sensation versus no pain. But pain elimination comes with a total lack of feeling in the lower body, due to ...
-
Wenzel Spine Announces Publication of Case Series Detailing Endoscopic Transforaminal Decompression and Fusion Technique with VariLift-LX
Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders, today announced a 24 Consecutive Patient Case Series detailing an endoscopic, stand-alone TLIF surgical technique used with the VariLift-LX System has been published in the Journal of Spine, Volume 7, Issue 2. The Case Series, authored by Kai-Uwe ...
-
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you